The Diagnostic Application of Radiolabelled Folate in the Detection of Folate Receptor-Positive Tumors.
Folate receptor (FR)-positive cancer, particularly in the ovary, is difficult to diagnose in the early stages of disease and is a poor prognosis for those involved. Currently, computed tomography (CT) and sonography are useful for assessing lesion size but are limited by the sensitivity, specificity, and resolution of the systems. Radiolabelled folates have been a topic of interest over recent years, and research is showing promising results. In particular, technetium -99m etarfolatide using single-photon emission computed tomography or single-photon emission computed tomography/CT has been claimed as the most practical and efficient radiocompound and can be used to diagnose FR-positive cancers and metastatic involvement. A conjugate chemotherapy treatment agent, EC145, uses the same pathway as technetium-99m EC20, and, therefore, these two agents can be used together to provide a new method of treatment. Some positron emission tomography/CT radiocompounds have also been explored based on similar disease pathways, but much more research is still needed. The purpose of this article was to discuss the role of radiolabelled folates in the diagnosis and management of patients with FR-positive ovarian cancer.